Cite
APA Citation
Kebenko, M., Goebeler, M., Wolf, M., Hasenburg, A., Seggewiss-Bernhardt, R., Ritter, B., Rautenberg, B., Atanackovic, D., Kratzer, A., Rottman, J. B., Friedrich, M., Vieser, E., Elm, S., Patzak, I., Wessiepe, D., Stienen, S., & Fiedler, W. (2018). a multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology, 7, . http://access.bl.uk/ark:/81055/vdc_100068019091.0x00000e